Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
about
Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association dataNew developments in the management of chronic lymphocytic leukemia: role of ofatumumabClinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemiaNew antibody approaches to lymphoma therapyEmerging Therapies for Rheumatoid ArthritisTherapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemiaInduced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.Ofatumumab combined with chlorambucil for previously untreated chronic lymphocytic leukemia: a phase I/II, open-label study in Japan.Patient-derived heavy chain antibody targets cell surface HSP90 on breast tumors.Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia.Initial treatment of CLL: integrating biology and functional status.A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine.Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.Targeted therapy for chronic lymphocytic leukemia: current status and future directions.Achieving incompatible transplantation through desensitization: current perspectives and future directions.Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).The use of ofatumumab in the treatment of B-cell malignancies.Ofatumumab for treating chronic lymphocytic leukemia: a safety profile.Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.Recent advances in therapy of chronic lymphocytic leukaemia.Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia.A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients.Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic lymphocytic leukemia: does one size fit all?Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia.
P2860
Q26738934-A841B8FC-C1EC-4767-B4BA-9A98A3105A00Q26768396-E38AEE7F-833B-473E-94B6-FFD325F2E4E2Q26783600-3F664308-F955-4A8D-93D9-625B384C753AQ27022373-40726781-553F-4BCA-8D9E-A74E137578CBQ28078943-DCBDC62D-A550-4232-A662-683193FB59A3Q28087378-AC9C2D63-57EA-4C90-80D7-96220D93D171Q30405847-809BAD14-65F2-4E91-B597-C85A71B59DE4Q33419843-80D3DC47-E216-473F-9E21-2E8FD2250EDFQ33441123-8C7C2CBE-A007-4F53-9453-A6852F00E8D5Q35763206-077AA75D-DA88-4DB4-97F4-1FA1453DBB58Q35953518-AC4FEEB5-6C96-49E2-9B18-46F08DCB8E80Q36065294-5E5CD8B1-A250-4450-9F4C-330E96F71887Q36219647-57924845-15A3-4C2F-BF40-1222847A65D7Q36965127-AA1D4F45-C606-4618-A392-E2E8B9960706Q38221686-4BF39C9D-DDCE-45C2-95A6-850F9F879E7CQ38331701-845FAE96-C9E7-4A6D-9762-723EC28CCBDFQ38445336-06690BFD-B1F9-4E60-8865-F26205A52F8DQ38579008-02D1EE98-AF12-4FDE-A21D-18893EAA1E4BQ38603992-EE0807C2-7B42-4117-8E04-622385CF129DQ38632940-0A535D8F-EF6C-4E14-9A67-C9FB0698F79FQ38764077-7C118870-7D5F-42BC-9F2E-1A7B9283EC16Q38862525-D2E63AFD-7382-49E2-8D85-7D5117973BACQ38916526-B524E52D-DBCF-4C5B-A6BB-EB41BC2FFFB3Q39018189-0118050F-0FD0-48DC-9409-95E69D859CFCQ39303346-0C877D97-7AA9-4D19-83D8-65CEB5D79F36Q41125227-F5FBB14E-6047-450E-98E3-58E53BD07C34Q43146957-7D7B6BD1-B6BC-4198-984F-A5E1ACF9D50CQ47309947-8C07B51A-B3C0-4524-BF7A-CDAF2AEE3A88Q47399742-7471AC98-B76E-4BC8-A1D3-53CBC1F276E8
P2860
Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ofatumumab-based chemoimmunoth ...... ic lymphocytic leukemia (CLL).
@en
Ofatumumab-based chemoimmunoth ...... d chronic lymphocytic leukemia
@nl
type
label
Ofatumumab-based chemoimmunoth ...... ic lymphocytic leukemia (CLL).
@en
Ofatumumab-based chemoimmunoth ...... d chronic lymphocytic leukemia
@nl
prefLabel
Ofatumumab-based chemoimmunoth ...... ic lymphocytic leukemia (CLL).
@en
Ofatumumab-based chemoimmunoth ...... d chronic lymphocytic leukemia
@nl
P2093
P2860
P356
P1433
P1476
Ofatumumab-based chemoimmunoth ...... ic lymphocytic leukemia (CLL).
@en
P2093
Anne W Beaven
Betsy LaPlant
Clive S Zent
Curtis A Hanson
Deborah Bowen
Diane F Jelinek
Jose F Leis
Mark C Lanasa
Michael Conte
Neil E Kay
P2860
P304
P356
10.1002/CNCR.28292
P407
P577
2013-08-06T00:00:00Z